| Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes |
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments |
globenewswire.com |
2025-05-13 05:36:00 |
Czytaj oryginał (ang.) |
| Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101 |
Galapagos NV released positive data from the phase 1/2 ATALANTA-1 study using GLPG5101 for the treatment of patients with relapsed/refractory Mantle Cell Lymphoma; 100% ORR/CR was achieved in 8 patients. Updated data from the relapsed/refractory Mantle Cell Lymphoma cohort from the phase 1/2 ATALANTA-1 study is to be presented at a medical conference presentation 2nd half of 2025. The global MCL market is expected to reach $5.77 billion by the end of 2034; Between 15% to 20% of MCL patients who receive front-line therapy progress within 2 years. |
seekingalpha.com |
2025-04-25 22:16:57 |
Czytaj oryginał (ang.) |
| Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript |
Galapagos NV (NASDAQ:GLPG ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Paul Stoffels - Chair, Chief Executive Officer Thad Huston - Chief Operating, Chief Financial Officer John Mellors - Head of Cell Therapy Discovery WulfBöcher - Head of Immunology Omotayo Fasan - Clinical Program Head, Oncology Valeria Cnossen - Executive and General Counsel Glenn Schulman - Head of Investor Relations Conference Call Participants Brian Abrahams - RBC Capital Markets Phil Nadeau - TD Cowan Sebastiaan van der Schoot - Van Lanschot Kempen Manos Mastorakis - Deutsche Bank Faisal Khurshid - Leerink Partners Judah Frommer - Morgan Stanley Jacob Mekhael - KBC Securities Chi Fong - Bank of America David Seynnaeve - DegroofPetercam Operator Good day! And thank you for standing by. |
seekingalpha.com |
2025-04-24 15:34:01 |
Czytaj oryginał (ang.) |
| Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts |
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million - €225 million reaffirmed Management to host conference call and webcast tomorrow, April 24, 2025, at 14:00 CET / 08:00 EDT Mechelen, Belgium; April 23, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & Nasdaq: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial and operational results for the first quarter of 2025. “We are making progress toward the planned separation announced early this year, positioning Galapagos to be a leader in cell therapy, focused on addressing the high unmet needs of patients with hematologic malignancies with our potential best-in-class cell therapies,” said Paul Stoffels1, MD, CEO and Chair of the Board of Directors of Galapagos. |
globenewswire.com |
2025-04-23 20:01:00 |
Czytaj oryginał (ang.) |
| Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 |
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months. Paul Stoffels1, MD, CEO and Chair of the Board of Directors of Galapagos, said “Over the past two years, Thad has worked on the transformation of Galapagos into a focused cell therapy business leveraging our unique decentralized cell therapy platform to deliver fresh, stem-like early memory CAR-T therapy with a vein-to-vein time of seven days. Thad will remain with the company until August 1, 2025 to ensure a smooth handover of responsibilities. We thank Thad for his contributions and wish him the best as he pursues other opportunities.” |
globenewswire.com |
2025-04-15 05:30:00 |
Czytaj oryginał (ang.) |
| Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting |
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company. |
globenewswire.com |
2025-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Galapagos to Present at Upcoming Investor Conferences |
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March: TD Cowen 45 th Annual Healthcare Conference Date: Tuesday, March 4, 2025Location: Boston, MACorporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CETLive Webcast Link: Here Barclays 27 th Annual Global Healthcare Conference Date: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25 AM ET / 5:00 - 5:25 PM CETLive Webcast Link: Here A live webcast of the presentations can also be accessed on the Investors page of the Company's website at www.glpg.com/investors. Replays of the webcasts will be available following the completion of the event and will be archived for up to 90 days. About Galapagos We are a biotechnology company with operations in Europe and the U.S. dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders. Our goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most. For additional information, please visit www.glpg.com or follow us on LinkedIn or X. For further information, please contact: |
globenewswire.com |
2025-02-24 18:01:00 |
Czytaj oryginał (ang.) |
| Disount To Net Cash For A Promising CAR-T Company |
Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell therapies and small molecules, while 'SpinCo' will target oncology, immunology, and virology with €2.45 billion in capital. Despite an 18% share decline post-announcement, the split offers deep value and potential catalysts, though risks include governance concerns, competitive CAR-T space, and executional challenges. |
seekingalpha.com |
2025-02-20 09:13:40 |
Czytaj oryginał (ang.) |
| Galapagos receives transparency notification and 13D filing from Tang Capital |
Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. |
globenewswire.com |
2025-02-17 18:01:00 |
Czytaj oryginał (ang.) |
| Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript |
Galapagos NV (NASDAQ:GLPG ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sri Ramaswami - Senior Vice President and Global Head of Corporate Affairs & Investor Relations Paul Stoffels - Chair of the Board & Chief Executive Officer Thad Huston - Chief Financial Officer & Chief Operating Officer Valeria Cnossen - General Counsel Jeevan Shetty - Head of Clinical Development Oncology John Mellors - Head of Cell Therapy Discovery & Early Development Conference Call Participants Xian Deng - UBS Phil Nadeau - TD Cowen Brian Abrahams - RBC Capital Markets Faisal Khurshid - Leerink Partners Judah Frommer - Morgan Stanley Sean McCutcheon - Raymond James Jacob Mekhael - KBC Securities Sebastiaan Van der Schoot - Van Lanschot Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2024 Financial Results and Business Update Conference Call. |
seekingalpha.com |
2025-02-13 15:26:39 |
Czytaj oryginał (ang.) |
| Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update |
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein |
globenewswire.com |
2025-02-12 18:01:00 |
Czytaj oryginał (ang.) |
| Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-02-05 12:36:11 |
Czytaj oryginał (ang.) |
| Galapagos To Spin Off Innovative Medicines Business |
Deal Overview |
forbes.com |
2025-01-21 14:08:16 |
Czytaj oryginał (ang.) |
| Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities |
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions |
globenewswire.com |
2025-01-08 03:30:00 |
Czytaj oryginał (ang.) |
| Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco. A live webcast of the presentation will be accessible on the Investors page of the Company's website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. In addition, Galapagos management will host a sell-side analyst breakfast in San Francisco on Tuesday, January 14, 2025 at 8:00 am PT. Analysts interested in attending should reach out the Galapagos Investor Relations team at ir@glpg.com. |
globenewswire.com |
2025-01-07 18:01:00 |
Czytaj oryginał (ang.) |
| Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma |
Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate an encouraging efficacy and safety profile in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Most patients in the study received GLPG5101 as a fresh, fit, stem-like, early memory CD19 CAR T-cell therapy, with a median vein-to-vein time of seven days. |
globenewswire.com |
2024-12-07 14:30:00 |
Czytaj oryginał (ang.) |
| Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 |
Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 7-10 December 2024. |
globenewswire.com |
2024-11-05 18:01:00 |
Czytaj oryginał (ang.) |
| Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript |
Galapagos NV (NASDAQ:GLPG ) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ET Company Participants Sofie Van Gijsel - Head of IR Paul Stoffels - Chair of the Board & CEO Thad Huston - CFO & COO Jeevan Shetty - Head of Development Oncology Wulf Bocher - Head Immunology Therapeutic Area Conference Call Participants Xian Deng - UBS Judah Frommer - Morgan Stanley Alexander Kelly - TD Cowen Shan Hama - Jefferies Nevin Varghese - RBC Capital Markets Jacob Mekhael - KBC Securities Faisal Khurshid - Leerink Partners Sebastiaan Van der Schoot - VLK Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2024 Financial Results Audio Webcast. |
seekingalpha.com |
2024-10-31 17:50:31 |
Czytaj oryginał (ang.) |
| Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update |
Webcast presentation on October 31, 2024, at 1 3 :00 CET / 8:00 am ET, www.glpg.com |
globenewswire.com |
2024-10-30 18:01:00 |
Czytaj oryginał (ang.) |
| Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth |
Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. |
globenewswire.com |
2024-10-07 05:00:00 |
Czytaj oryginał (ang.) |
| Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area |
SAN DIEGO--(BUSINESS WIRE)--Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO) member of Blood Centers of America (BCA), today announced that it has been selected to manufacture Galapagos' CAR-T cell therapy candidate, GLPG5101, for its recently FDA cleared ATALANTA-1 clinical study in patients with relapsed/refractory non-Hodgkin lymphoma in the U.S. Galapagos (Euronext & Nasdaq: GLPG) is a clinical stage biotechnology company with operations in Europe. |
businesswire.com |
2024-10-01 10:00:00 |
Czytaj oryginał (ang.) |
| Galapagos receives transparency notification from EcoR1 Capital |
Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. |
globenewswire.com |
2024-09-30 20:01:00 |
Czytaj oryginał (ang.) |
| Galapagos receives transparency notification from EcoR1 Capital |
Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. |
globenewswire.com |
2024-09-16 20:01:00 |
Czytaj oryginał (ang.) |
| Galapagos receives transparency notification from FMR LLC |
Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. |
globenewswire.com |
2024-09-03 20:01:00 |
Czytaj oryginał (ang.) |
| Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats |
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people. |
investors.com |
2024-08-26 14:21:35 |
Czytaj oryginał (ang.) |
| Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond |
Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL; phase 1 portion with 87.5% ORR and phase 2 portion with 93.3% ORR. The global non-Hodgkin Lymphoma market is expected to reach $16 billion by 2029; on average, between 30% to 40% of NHL patients have relapsed/refractory disease. IND clearance of U.S. phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL achieved; this trial could speed up enrollment and further establish efficacy with newly added patients. |
seekingalpha.com |
2024-08-23 19:49:17 |
Czytaj oryginał (ang.) |